Abstract: The invention relates to the field of Hydrangea, specifically, the variety designated ‘HMOPICO04-0’. The variety ‘HMOPICO04-0’ is characterized by its lack of vernalization requirement for induction and development of flowering, day-length neutral flowering, cold tolerance to USDA Zone 5 and lace-cap inflorescence having pink and white flowers. The present invention relates to plant parts, including cells and any propagative material of the new variety ‘HMOPICO04-0’, use of any of the plant parts for reproducing the new variety ‘HMOPICO04-0’. The present invention relates to methods using any plant parts or progeny of ‘HMOPICO04-0’ for the purpose of deriving additional new Hydrangea varieties. The present invention relates to seed, plants and plant parts produced by crossing ‘HMOPICO04-0’ with any other Hydrangea variety or other plant. The present invention also relates to methods to produce new varieties of Hydrangea oleracea using the variety ‘HMOPICO04-0’ and applying plant breeding techniques.

Abstract: The invention relates to the field of Hydrangea, specifically, the variety designated ‘HMOWH05-0’. The variety ‘HMOWH05-0’ is characterized by its lack of vernalization requirement for induction and development of flowering, day-length neutral flowering, cold tolerance to USDA Zone 5 and lace-cap inflorescence having white sterile flowers and pink fertile flowers. The present invention relates to plant parts, including cells and any propagative material of the new variety ‘HMOWH05-0’, and use of any of the plant parts for reproducing the new variety ‘HMOWH05-0’. The present invention relates to methods using any plant parts or progeny of ‘HMOWH05-0’ for the purpose of deriving additional new Hydrangea varieties. The present invention relates to seed, plants and plant parts produced by crossing ‘HMOWH05-0’ with any other Hydrangea variety or other plant. The present invention also relates to methods to produce new varieties of Hydrangea using the variety ‘HMOWH05-0’ and applying plant breeding techniques.

Abstract: The invention relates to the field of Hydrangea, specifically, the variety designated ‘HMOPICO04-0’. The variety ‘HMOPICO04-0’ is characterized by its lack of vernalization requirement for induction and development of flowering, day-length neutral flowering, cold tolerance to USDA Zone 5 and lace-cap inflorescence having pink and white flowers. The present invention relates to plant parts, including cells and any propagative material of the new variety ‘HMOPICO04-0’, use of any of the plant parts for reproducing the new variety ‘HMOPICO04-0’. The present invention relates to methods using any plant parts or progeny of ‘HMOPICO04-0’ for the purpose of deriving additional new Hydrangea varieties. The present invention relates to seed, plants and plant parts produced by crossing ‘HMOPICO04-0’ with any other Hydrangea variety or other plant. The present invention also relates to methods to produce new varieties of Hydrangea oleracea using the variety ‘HMOPICO04-0’ and applying plant breeding techniques.

Abstract: The invention relates to the field of Hydrangea, specifically, the variety designated ‘HMOPI02-0’. The variety ‘HMOPI02-0’ is characterized by its lack of vernalization requirement for induction and development of flowering, day-length neutral flowering, cold tolerance to USDA Zone 5 and lace-cap inflorescence having pink flowers. The present invention relates to plant parts, including cells and any propagative material of the new variety ‘HMOPI02-0’, and use of any of the plant parts for reproducing the new variety ‘HMOPI02-0’. The present invention relates to methods using any plant parts or progeny of ‘HMOPI02-0’ for the purpose of deriving additional new Hydrangea varieties. The present invention relates to seed, plants and plant parts produced by crossing ‘HMOPI02-0’ with any other Hydrangea variety or other plant. The present invention also relates to methods to produce new varieties of Hydrangea oleracea using the variety ‘HMOPI02-0’ and applying plant breeding techniques.

Abstract: The invention relates to the field of Rudbeckia hirta, specifically, the variety designated ‘RDSGO01-0’. The variety ‘RDSGO01-0’ is characterized by day-length neutral flowering, cold tolerance to USDA Zone 5 and abundant flowering of single infloresences with golden yellow ray florets. The present invention relates to plant parts, including cells and any propagative material of the new variety ‘RDSGO01-0’, and use of any of the plant parts for reproducing the new variety ‘RDSGO01-0’. The present invention relates to methods using any plant parts or progeny of ‘RDSGO01-0’ for the purpose of deriving additional new Rudbeckia hirta varieties. The present invention relates to seed, plants and plant parts produced by crossing ‘RDSGO01-0’ with any other Rudbeckia hirta variety or other plant. The present invention also relates to methods to produce new varieties of Rudbeckia hirta oleracea using the variety ‘RDSGO01-0’ and applying plant breeding techniques.

Abstract: The invention relates to the field of Hydrangea, specifically, the variety designated ‘HMOBL03-0’. The variety ‘HMOBL03-0’ is characterized by its lack of vernalization requirement for induction and development of flowering, day-length neutral flowering, cold tolerance to USDA Zone 5 and lace-cap inflorescence having blue flowers. The present invention relates to plant parts, including cells and any propagative material of the new variety ‘HMOBL03-0’, and use of any of the plant parts for reproducing the new variety ‘HMOBL03-0’. The present invention relates to methods using any plant parts or progeny of ‘HMOBL03-0’ for the purpose of deriving additional new Hydrangea varieties. The present invention relates to seed, plants and plant parts produced by crossing ‘HMOBL03-0’ with any other Hydrangea variety or other plant. The present invention also relates to methods to produce new varieties of Hydrangea oleracea using the variety ‘HMOBL03-0’ and applying plant breeding techniques.

Abstract: A new and distinct Rudbeckia hirta cultivar named ‘RRISU01-0’ is disclosed, characterized by early season flowering. Plants exhibit exceptional cold hardiness for the species and can be successfully propagated by conventional vegetative cuttings. The new variety is an Rudbeckia, and is normally used as a garden or container plant.

Abstract: There are described 4-difluoromethoxyphenyl pyrazolo[5.1-b]oxazole derivatives useful as corticotropin releasing factor (CRF1) receptor antagonists.

Abstract: A compound of Formula I or a hydrate or solvate thereof, where R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 have the meanings as indicated in the specification, is useful for treating diseases which respond to the blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

Abstract: There are described 4-difluoromethoxyphenyl pyrazolo[5.1-b]oxazole derivatives of Formula I: which are useful as corticotropin releasing factor (CRF) receptor antagonists and as pharmaceuticals.

Abstract: There are described cyclohexyl amide derivatives of Formula I, which are useful as corticotropin releasing factor (CRF) receptor antagonists and as pharmaceuticals.

Abstract: A compound of Formula I or a hydrate or solvate thereof, where R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 have the meanings as indicated in the specification, is useful for treating diseases which respond to the blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

Abstract: There are described pyrazolo[5.1-b]oxazole derivatives useful as corticotropin releasing factor (CRF1) receptor antagonists.

Abstract: There are described 4-difluoromethoxyphenyl pyrazolo[5.1-b]oxazole derivatives of Formula I: which are useful as corticotropin releasing factor (CRF) receptor antagonists and as pharmaceuticals.

Abstract: Compounds of formula I in salt or zwitterionic form wherein, wherein R1, R2, R3, and R4 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by the muscarinic M3 receptor. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.

Abstract: There are described pyrazolo[5.1-b]oxazole derivatives useful as corticotropin releasing factor (CRF1) receptor antagonists.

Abstract: A new and distinct Rudbeckia hirta cultivar named ‘RRISU01-0’ is disclosed, characterized by early season flowering. Plants exhibit exceptional cold hardiness for the species and can be successfully propagated by conventional vegetative cuttings. The new variety is an Rudbeckia, and is normally used as a garden or container plant.